Show simple item record

dc.contributor.authorOliveira, M.
dc.contributor.authorHamilton, E. P.
dc.contributor.authorIncorvati, J.
dc.contributor.authorde la Heras, B. B.
dc.contributor.authorCalvo, E.
dc.contributor.authorGarcia-Corbacho, J.
dc.contributor.authorRuiz-Borrego, M.
dc.contributor.authorVaklavas, C.
dc.contributor.authorTurner, N. C.
dc.contributor.authorCiruelos, E. M.
dc.contributor.authorPatel, M. R.
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorKabos, P.
dc.contributor.authorTwelves, C.
dc.contributor.authorBrier, T.
dc.contributor.authorIrurzun-Arana, I.
dc.contributor.authorKlinowska, T.
dc.contributor.authorLindemann, J. P. O.
dc.contributor.authorMorrow, C. J.
dc.contributor.authorBaird, R. D.
dc.date.accessioned2022-11-30T10:21:23Z
dc.date.available2022-11-30T10:21:23Z
dc.date.issued2022en
dc.identifier.citationOliveira M, Hamilton EP, Incorvati J, de la Heras BB, Calvo E, Garcia-Corbacho J, et al. Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300091.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.1032en
dc.identifier.urihttp://hdl.handle.net/10541/625793
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.1032en
dc.titleSerena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVall d'Hebron Institute of Oncology (VHIO), Barcelona,en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record